---
document_datetime: 2025-11-23 08:05:55
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/riprazo-hct.html
document_name: riprazo-hct.html
version: success
processing_time: 0.105344
conversion_datetime: 2025-12-27 14:27:02.188648
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Riprazo HCT

[RSS](/en/individual-human-medicine.xml/66949)

##### Withdrawn

This medicine's authorisation has been withdrawn

aliskiren / hydrochlorothiazide

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Riprazo HCT](#news-on)
- [More information on Riprazo HCT](#more-information-on-riprazo-hct-1490)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 13 April 2011 the European Commission issued a marketing authorisation valid throughout the European Union for the medicinal product Riprazo HCT (aliskiren/hydrochlorothiazide). Riprazo HCT was approved for the treatment of essential hypertension. The marketing authorisation holder (MAH) responsible for Riprazo HCT was Novartis Europharm Ltd.

The European Commission was notified by letter dated 26 July 2012 of the MAH's decision to voluntarily withdraw the marketing authorisation for Riprazo HCT for commercial reasons. On 30 August 2012 the European Commission issued a decision to withdraw the marketing authorisation for Riprazo HCT.

Pursuant to this decision the European Public Assessment Report for Rprazo HCT is updated to reflect the fact that the marketing authorisation is no longer valid.

Riprazo HCT  : EPAR - Summary for the public

Reference Number: EMA/106444/2011

English (EN) (259.13 KB - PDF)

**First published:** 29/09/2011

**Last updated:** 20/09/2012

[View](/en/documents/overview/riprazo-hct-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-666)

български (BG) (404.15 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/bg/documents/overview/riprazo-hct-epar-summary-public_bg.pdf)

español (ES) (275.87 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/es/documents/overview/riprazo-hct-epar-summary-public_es.pdf)

čeština (CS) (313.36 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/cs/documents/overview/riprazo-hct-epar-summary-public_cs.pdf)

dansk (DA) (319.29 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/da/documents/overview/riprazo-hct-epar-summary-public_da.pdf)

Deutsch (DE) (321.53 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/de/documents/overview/riprazo-hct-epar-summary-public_de.pdf)

eesti keel (ET) (333.81 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/et/documents/overview/riprazo-hct-epar-summary-public_et.pdf)

ελληνικά (EL) (349.39 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/el/documents/overview/riprazo-hct-epar-summary-public_el.pdf)

français (FR) (336.54 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/fr/documents/overview/riprazo-hct-epar-summary-public_fr.pdf)

italiano (IT) (260.9 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/it/documents/overview/riprazo-hct-epar-summary-public_it.pdf)

latviešu valoda (LV) (317.53 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/lv/documents/overview/riprazo-hct-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (343.96 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/lt/documents/overview/riprazo-hct-epar-summary-public_lt.pdf)

magyar (HU) (368.19 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/hu/documents/overview/riprazo-hct-epar-summary-public_hu.pdf)

Malti (MT) (374.19 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/mt/documents/overview/riprazo-hct-epar-summary-public_mt.pdf)

Nederlands (NL) (320.19 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/nl/documents/overview/riprazo-hct-epar-summary-public_nl.pdf)

polski (PL) (374.3 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/pl/documents/overview/riprazo-hct-epar-summary-public_pl.pdf)

português (PT) (319.04 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/pt/documents/overview/riprazo-hct-epar-summary-public_pt.pdf)

română (RO) (284.34 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/ro/documents/overview/riprazo-hct-epar-summary-public_ro.pdf)

slovenčina (SK) (312.8 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/sk/documents/overview/riprazo-hct-epar-summary-public_sk.pdf)

slovenščina (SL) (308.75 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/sl/documents/overview/riprazo-hct-epar-summary-public_sl.pdf)

Suomi (FI) (275.25 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/fi/documents/overview/riprazo-hct-epar-summary-public_fi.pdf)

svenska (SV) (260.24 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/sv/documents/overview/riprazo-hct-epar-summary-public_sv.pdf)

## Product information

Riprazo HCT  : EPAR - Product Information

English (EN) (1.84 MB - PDF)

**First published:** 29/09/2011

**Last updated:** 20/09/2012

[View](/en/documents/product-information/riprazo-hct-epar-product-information_en.pdf)

[Other languages (23)](#file-language-dropdown-790)

български (BG) (4.65 MB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/bg/documents/product-information/riprazo-hct-epar-product-information_bg.pdf)

español (ES) (1.8 MB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/es/documents/product-information/riprazo-hct-epar-product-information_es.pdf)

čeština (CS) (3.28 MB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/cs/documents/product-information/riprazo-hct-epar-product-information_cs.pdf)

dansk (DA) (1.84 MB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/da/documents/product-information/riprazo-hct-epar-product-information_da.pdf)

Deutsch (DE) (1.86 MB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/de/documents/product-information/riprazo-hct-epar-product-information_de.pdf)

eesti keel (ET) (2.06 MB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/et/documents/product-information/riprazo-hct-epar-product-information_et.pdf)

ελληνικά (EL) (4.82 MB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/el/documents/product-information/riprazo-hct-epar-product-information_el.pdf)

français (FR) (2.19 MB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/fr/documents/product-information/riprazo-hct-epar-product-information_fr.pdf)

íslenska (IS) (2 MB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/is/documents/product-information/riprazo-hct-epar-product-information_is.pdf)

italiano (IT) (1.91 MB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/it/documents/product-information/riprazo-hct-epar-product-information_it.pdf)

latviešu valoda (LV) (3.47 MB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/lv/documents/product-information/riprazo-hct-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.04 MB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/lt/documents/product-information/riprazo-hct-epar-product-information_lt.pdf)

magyar (HU) (3.35 MB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/hu/documents/product-information/riprazo-hct-epar-product-information_hu.pdf)

Malti (MT) (3.59 MB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/mt/documents/product-information/riprazo-hct-epar-product-information_mt.pdf)

Nederlands (NL) (1.92 MB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/nl/documents/product-information/riprazo-hct-epar-product-information_nl.pdf)

norsk (NO) (1.95 MB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/no/documents/product-information/riprazo-hct-epar-product-information_no.pdf)

polski (PL) (3.54 MB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/pl/documents/product-information/riprazo-hct-epar-product-information_pl.pdf)

português (PT) (1.85 MB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/pt/documents/product-information/riprazo-hct-epar-product-information_pt.pdf)

română (RO) (2.04 MB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/ro/documents/product-information/riprazo-hct-epar-product-information_ro.pdf)

slovenčina (SK) (3.38 MB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/sk/documents/product-information/riprazo-hct-epar-product-information_sk.pdf)

slovenščina (SL) (3.33 MB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/sl/documents/product-information/riprazo-hct-epar-product-information_sl.pdf)

Suomi (FI) (1.82 MB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/fi/documents/product-information/riprazo-hct-epar-product-information_fi.pdf)

svenska (SV) (1.81 MB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/sv/documents/product-information/riprazo-hct-epar-product-information_sv.pdf)

30/08/2012

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Riprazo HCT  : EPAR - All Authorised presentations

English (EN) (424.92 KB - PDF)

**First published:** 29/09/2011

**Last updated:** 20/09/2012

[View](/en/documents/all-authorised-presentations/riprazo-hct-epar-all-authorised-presentations_en.pdf)

[Other languages (23)](#file-language-dropdown-621)

български (BG) (513.46 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/bg/documents/all-authorised-presentations/riprazo-hct-epar-all-authorised-presentations_bg.pdf)

español (ES) (423.95 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/es/documents/all-authorised-presentations/riprazo-hct-epar-all-authorised-presentations_es.pdf)

čeština (CS) (472.69 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/cs/documents/all-authorised-presentations/riprazo-hct-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (421.58 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/da/documents/all-authorised-presentations/riprazo-hct-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (426.66 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/de/documents/all-authorised-presentations/riprazo-hct-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (430.33 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/et/documents/all-authorised-presentations/riprazo-hct-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (534.39 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/el/documents/all-authorised-presentations/riprazo-hct-epar-all-authorised-presentations_el.pdf)

français (FR) (436.35 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/fr/documents/all-authorised-presentations/riprazo-hct-epar-all-authorised-presentations_fr.pdf)

íslenska (IS) (419.06 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/is/documents/all-authorised-presentations/riprazo-hct-epar-all-authorised-presentations_is.pdf)

italiano (IT) (422.76 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/it/documents/all-authorised-presentations/riprazo-hct-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (453.55 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/lv/documents/all-authorised-presentations/riprazo-hct-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (453.49 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/lt/documents/all-authorised-presentations/riprazo-hct-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (481.08 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/hu/documents/all-authorised-presentations/riprazo-hct-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (451.27 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/mt/documents/all-authorised-presentations/riprazo-hct-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (422.66 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/nl/documents/all-authorised-presentations/riprazo-hct-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (451.96 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/no/documents/all-authorised-presentations/riprazo-hct-epar-all-authorised-presentations_no.pdf)

polski (PL) (447.39 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/pl/documents/all-authorised-presentations/riprazo-hct-epar-all-authorised-presentations_pl.pdf)

português (PT) (423.52 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/pt/documents/all-authorised-presentations/riprazo-hct-epar-all-authorised-presentations_pt.pdf)

română (RO) (424.37 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/ro/documents/all-authorised-presentations/riprazo-hct-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (476.97 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/sk/documents/all-authorised-presentations/riprazo-hct-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (474.34 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/sl/documents/all-authorised-presentations/riprazo-hct-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (424.62 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/fi/documents/all-authorised-presentations/riprazo-hct-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (425.95 KB - PDF)

**First published:**

29/09/2011

**Last updated:**

20/09/2012

[View](/sv/documents/all-authorised-presentations/riprazo-hct-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Riprazo HCT Active substance

- aliskiren
- hydrochlorothiazide

International non-proprietary name (INN) or common name

- aliskiren
- hydrochlorothiazide

Therapeutic area (MeSH) Hypertension Anatomical therapeutic chemical (ATC) code C09XA52

### Pharmacotherapeutic group

Agents acting on the renin-angiotensin system

### Therapeutic indication

Treatment of essential hypertension in adults.

Riprazo HCT is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone.

Rirpozo HCT is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.

## Authorisation details

EMA product number EMEA/H/C/002420 Marketing authorisation holder

Novartis Europharm Ltd.

Wimblehurst Road

Marketing authorisation issued 13/04/2011 Withdrawal of marketing authorisation 30/08/2012

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Riprazo HCT  : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (321.05 KB - PDF)

**First published:** 20/09/2012

**Last updated:** 20/09/2012

[View](/en/documents/procedural-steps-after/riprazo-hct-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Riprazo HCT-H-C-2420-A20-15  : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/391001/2012

English (EN) (501.5 KB - PDF)

**First published:** 20/09/2012

**Last updated:** 20/09/2012

[View](/en/documents/variation-report/riprazo-hct-h-c-2420-a20-15-epar-assessment-report-variation_en.pdf)

Riprazo HCT-H-C-2420-WS-169  : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/479606/2012

English (EN) (385.15 KB - PDF)

**First published:** 20/09/2012

**Last updated:** 20/09/2012

[View](/en/documents/variation-report/riprazo-hct-h-c-2420-ws-169-epar-assessment-report-variation_en.pdf)

## Initial marketing authorisation documents

Riprazo HCT  : EPAR - Public assessment report

Adopted

Reference Number: EMA/745107/2011

English (EN) (308.02 KB - PDF)

**First published:** 29/09/2011

**Last updated:** 20/09/2012

[View](/en/documents/assessment-report/riprazo-hct-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Riprazo HCT

Adopted

Reference Number: EMA/35671/2011

English (EN) (56.27 KB - PDF)

**First published:** 21/01/2011

**Last updated:** 21/01/2011

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-riprazo-hct_en.pdf)

#### News on Riprazo HCT

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 February 2012](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-february-2012) 17/02/2012

#### More information on Riprazo HCT

Questions and answers on the review aliskiren-containing medicines

Reference Number: EMA/113677/2012

English (EN) (60.98 KB - PDF)

**First published:** 17/02/2012

**Last updated:** 17/02/2012

[View](/en/documents/medicine-qa/questions-and-answers-review-aliskiren-containing-medicines_en.pdf)

Questions and answers on ongoing review of aliskiren-containing medicines

Reference Number: EMA/990270/2011

English (EN) (65.3 KB - PDF)

**First published:** 22/12/2011

**Last updated:** 22/12/2011

[View](/en/documents/medicine-qa/questions-and-answers-ongoing-review-aliskiren-containing-medicines_en.pdf)

**This page was last updated on** 20/09/2012

## Share this page

[Back to top](#main-content)